Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line

Inclusion Criteria: 1. Patient with diffuse large-cell B lymphoma regardless of the WHO 2016 classification subtype, or low-grade B lymphoma immediately transformed into high-grade B lymphoma (follicular lymphoma of the marginal zone, MALT, lymphocytic, lympho-plasma cells), 2. Treatment naïve or having benefited from 2 cycles of chemotherapy (prephase or COP and cycle n ° 1 of RCHOP) if Performance Status\> 3 linked to hemopathy and reversible (≤ 2) 3. Aged ≥ 65 years old, 4. Eligible for treatment with RCHOP, regardless of the IPI score adjusted for age, 5. Performance Status ≤ 2, 6. Patient affiliated to a social security scheme, 7. Patient who has given written consent before any specific procedure related to the study Exclusion Criteria: 1. Any other type of lymphoma (T lymphoma, Burkitt's lymphoma, non-transformed low-grade B lymphoma, etc.), 2. Cerebral or meningeal damage related to hemopathy, 3. Acquired or congenital motor or sensory deficit which does not allow the completion of APA sessions, 4. Uncontrolled arterial hypertension, 5. Disabling heart or respiratory failure not allowing the completion of APA sessions, 6. Disabling osteo-articular or muscular pathology, 7. LVEF \<50%, 8. Patient having received 3 or more cycles of 1st line chemotherapy, 9. Pregnancy or breastfeeding, 10. Active viral infection: hepatitis B, C and HIV, 11. Persons deprived of their liberty or under guardianship 12. Dementia, mental alteration or psychiatric pathology which could compromise the patient's informed consent and / or compliance with the protocol and follow-up of the trial, 13. Patient who can't follow protocol for psychological, social, family or geographic reasons